share_log

Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target

Benzinga ·  Mar 29, 2023 07:58

Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment